Table 1.

Clinical findings on diseased participants treated with resveratrol.

Disease	No. of Treated Subjects (Males, Females or Both)	Dose of Resveratrol	Duration of Treatment in Days	Important Findings	Reference
T2DM	57 (Both)	250 mg	120	Ameliorated profiles of lipids (total cholesterol by 7.8%), total proteins (by 4.36%) and hemoglobin A1c (by 3.4%)	[12]
T2DM	19 (Males)	5 mg	30	Reduced blood glucose levels and ameliorated insulin resistance	[13]
T2DM	35 (Males)	8 mg	365	Down-regulation of various cytokines including CCL3 and TNF	[14]
Obesity	8 (Both)	1000–2000 mg	14	Non-significant effect on lipid profile but lowered synthesis of apoB-48 and apoB-100	[15]
Obesity	74 (Males)	500 mg	105	Increased bone density	[16]
Obesity	19 (Both)	30, 90 or 270 mg	21	Significantly elevated FMD	[17]
Impaired glucose tolerance (Obesity)	10 (Both)	1000–2000 mg	28	Ameliorated insulin sensitivity	[18]
Metabolic syndrome (obesity)	24 (Both)	500 mg	90	Significantly reduced weight, BMI, fat mass, and weight, Significant effect on insulin sensitivity.	[19]
Non-alcoholic fatty liver disease	20 (Males)	3000 mg	56	Non-significant effect on insulin function and fat distribution	[20]
Non-alcoholic fatty liver disease	49 (Both)	500 mg	84	Significant decline in hepatic inflammatory markers	[21]
Colorectal cancer and hepatic metastases	9 (Both)	5000 g	21	Excellent distribution of RSV in body	[5]
Colorectal cancer	20 (Both)	500 mg	8	Reduced proliferation in in cancerous tissue	[22]
Colon cancer	8 (Both)	80 mg	14	No effect on Wnt signaling in cancerous mucosa	[9]
Breast cancer	31 (Females)	5 or 50 mg	84	Modified methylation of RASSF-1 (an indicator of breast cancer)	[23]
Angina pectoris	116 (Both)	20 mg	60	Significant decline in hs-CRP	[24]
Coronary heart disease	75 (Both)	8 mg	365	Elevated levels of adiponectin and decrease in PAI-1	[25]
Myocardial infarction	40 (Both)	10 mg	120	Ameliorated functioning of endothelium and left ventricle as well as reduced level of LDL	[26]